Evaluation of efficacy and safety of ceftazidime-avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis

The increasing prevalence of resistance to present available antibiotics for bacterial infections, especially for complicated infections evoked by gram-negative bacteria (GNB) is still a challenge [1]. Currently, carbapenems (CB) are the first-line recommended therapy for patients with severe infections [2]. However, there is concern that the extensively utilization of CB may result in increasing incidence of resistant strains, in particular carbapenem-resistant enterobacteriaceae (CRE) [3,4]. Hence, it is important to use CB selectively and to develop more effective agents [5].
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Tags: Review Source Type: research